|1.||Dehpour, Ahmad Reza: 10 articles (09/2015 - 06/2002)|
|2.||Moezi, Leila: 7 articles (07/2015 - 12/2006)|
|3.||Shafaroodi, Hamed: 6 articles (07/2015 - 12/2006)|
|4.||Lu, Jia: 6 articles (02/2005 - 02/2003)|
|5.||Kern, T S: 6 articles (10/2004 - 10/2000)|
|6.||Moochhala, Shabbir M: 5 articles (02/2005 - 08/2003)|
|7.||Jerums, G: 5 articles (01/2004 - 01/2000)|
|8.||Ito, Yoshimasa: 4 articles (11/2008 - 02/2003)|
|9.||Kumar, Dinesh: 4 articles (07/2007 - 05/2004)|
|10.||Tandan, Surendra K: 4 articles (07/2007 - 05/2004)|
|1.||Diabetic Nephropathies (Diabetic Nephropathy)
07/01/2002 - "The efficacy of aminoguanidine (AG) on primary prevention of diabetic nephropathy was investigated in a nonhuman primate model of Type 1 diabetes over a period of 4 years. "
03/01/2000 - "Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy."
04/01/2002 - "Preliminary studies suggest a beneficial effect of pimagedine in treating patients with diabetic nephropathy. "
04/13/1999 - "Rather unexpectedly, the assay also led to the clear demonstration that the well-known AGE inhibitor aminoguanidine, currently in Phase 3 clinical trials for treatment of diabetic nephropathy, has negligible Amadorin activity. "
08/01/1996 - "In addition, it was determined if aminoguanidine was more effective if administered earlier or later in the evolution of diabetic nephropathy by treating diabetic rats with aminoguanidine in the first or second half of the 32-week study period. "
08/01/1996 - "Aminoguanidine (320 mg/kg IP) administered 15 minutes after the onset of ischemia resulted in a significant reduction of infarct volume (7.6 +/- 2.6% of hemisphere in controls versus 1.3 +/- 0.2% of hemisphere in aminoguanidine-treated rats; P < .05). "
07/01/2011 - "The present work was designed to investigate the potential protective effects of post-ischemic treatment with aminoguanidine (AG) on sciatic nerve ischemia/reperfusion (I/R) injury in rat. "
02/01/2006 - "Aminoguanidine has the protective effects on the lungs against the total hepatic ischemia-reperfusion induced injury."
08/01/2012 - "The role of iNOS was assessed by measuring myocardial iNOS content and by observing the effects of the iNOS inhibitor aminoguanidine (Ag, 100 μm, prior to ischemia). "
03/01/2011 - "Our findings demonstrate that aminoguanidine decreases ischemic brain damage and improves neurological recovery after transient focal ischemia induced by MCAO."
10/01/1996 - "These can be used as endpoints in evaluating the efficacy of pharmacological agents such as aminoguanidine in preventing diabetic complications."
09/01/2011 - "The present study suggests that treatment using glycation inhibitors like aminoguanidine or recombinant sRAGE will not only retard the diabetic complications, but may also have a prophylactic effect."
02/01/2001 - "Agents used for the treatment of advanced glycated end-product accumulation are reviewed, with an emphasis on the results of the recent phase III trials using aminoguanidine and diabetes related complications."
10/01/2009 - "There is good evidence supporting the notion that aminoguanidine(AG)-derived compounds prevent glycation/glycooxidation-dependent processes and therefore inhibit late diabetic complications. "
03/01/1999 - "AGE inhibitors such as aminoguanidine have been shown to have beneficial effects on the progression of a full range of diabetic complications in animal models. "
01/01/2000 - "These findings suggest that acute treatment of the microcirculation in vivo with aminoguanidine ameliorates basal increases in extravasation of macromolecules during diabetes mellitus. "
01/01/2000 - "The goal of this study was to determine the effect of aminoguanidine on basal macromolecular efflux from the microcirculation of the hamster cheek pouch during diabetes mellitus. "
11/01/1997 - "Aminoguanidine and the prevention of leukocyte dysfunction in diabetes mellitus: a direct vital microscopic study."
09/01/2012 - "The effects of the inhibition of nitrosative stress by aminoguanidine in an experimental model of diabetes mellitus (DM) were investigated. "
07/01/2010 - "In this experimental model of diabetes mellitus, aminoguanidine reduced oxidative stress, structural tissue alterations, and gas exchange."
11/01/2002 - "Finally, a 12-week treatment period eliminated the bacilli completely and aminoguanidine did not induce reactivation of infection. "
02/01/1998 - "Cultures of RAW264.7 cells treated with IFN-gamma plus lipopolysaccharide exhibited suppression of the initial rickettsial infection, and the suppression was relieved by aminoguanidine. "
05/01/2011 - "Our data indicate that the two quadruple rpf deletion mutants, ΔACBD and ΔACDE, both display significant attenuation in the mouse lungs after aerosol infection, with no observable increase in bacillary loads upon aminoguanidine-induced immune suppression. "
09/01/2005 - "The importance of NO in systemic infection with the mutant strain was confirmed by the strong increase in the susceptibility of aminoguanidine (an iNOs inhibitor)-treated mice."
04/25/2003 - "Animals treated with aminoguanidine (AG), an iNOS inhibitor, showed a dose-dependent increase in vaginal pathology after viral infection compared to controls. "
|1.||NG-Nitroarginine Methyl Ester (L-NAME)
|2.||Nitric Oxide Synthase (NO Synthase)
|3.||Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)
|4.||Nitric Oxide (Nitrogen Monoxide)
|8.||Proteins (Proteins, Gene)
|9.||Sodium Chloride (Saline Solution)
|5.||Heterologous Transplantation (Xenotransplantation)